Injective Launches On-Chain Pre-IPO Stocks for OpenAI, SpaceX, and Anthropic
On May 11, 2026, Injective became the first layer-1 blockchain to list tokenized pre-IPO shares of OpenAI, SpaceX, and Anthropic for on-chain trading. The launch went live this week, dropping tokenized real-world assets directly into the AI trade instead of another sleepy treasury wrapper. I’ll be honest: this is the most interesting thing that has hit the RWA category in months. Per Injective’s announcement, anyone with a wallet can now get exposure to OpenAI, SpaceX, and Anthropic. Those names spent years sitting behind venture-capital gates. For a crypto market still looking for its next clean story after the spot-ETF cycle cooled off, this one has actual pull.
Pre-IPO tokenization means issuing on-chain digital representations of equity in private companies that have not yet gone public. Simple idea. Messy execution. Until now, getting exposure to OpenAI, SpaceX, or Anthropic meant writing a very large check or knowing the right partner at a venture fund. Neither route helps a normal trader much. Injective’s pitch is blunt: tokenize the shares, put them on-chain, and let wallet users trade them. Private markets have always been gated, locked for years, and reserved for accredited capital. Bain & Company’s 2025 Global Private Equity Report puts the global private equity market at over $13 trillion, yet almost none of that liquidity has ever behaved like a public market.
The launch did not come out of nowhere. It is the third stage of a roadmap Injective has been running since mid-2025. In October 2025, the protocol shipped pre-IPO perpetual futures: synthetic contracts that let traders speculate on private company valuations without holding shares. Per Injective’s on-chain data, that experiment did $1 billion in trading volume inside the first 30 days. Before that, in August 2025, Injective partnered with Republic, the retail-focused private deals platform, to tokenize private shares. Republic supplied the bridge between traditional private markets and Injective’s on-chain rails. The pre-IPO stocks announced May 11 are the visible payoff.
Why these three companies? Because OpenAI, SpaceX, and Anthropic are the three private tech names retail actually talks about. OpenAI is the face of the generative AI boom. Anthropic, the maker of Claude, has pulled in massive backing from Amazon and Google and is widely treated as OpenAI’s chief rival. SpaceX needs no warm-up act. Stanford’s 2025 AI Index Report says the broader AI sector took in over $100 billion in funding during 2024 alone, and there is still no public ticker for any of these names. My take: Injective is not just selling tokenized equity here. It is selling access to a market people already feel locked out of.
Most RWA guides say the future is tokenized treasuries and institution-friendly funds. That’s only half right. The angle here works because it is louder, riskier, and much more retail-facing. Tokenized treasuries and tokenized funds have been the dominant RWA story so far: useful, slow-moving, and, if I’m being honest, a little boring. Tokenized shares of OpenAI, SpaceX, and Anthropic hit differently. They bring AI-narrative beta. They give traders a reason to open a wallet on Injective. INJ is the protocol token that captures fee flow from this activity, and any sustained volume on these markets feeds directly into Injective’s burn auction mechanics. The October perp launch doing $1 billion in 30 days is the template. If spot-like tokenized stocks do even a fraction of that, INJ has a fundamentals story traders can actually point to.
Now the uncomfortable part. Tokenized stocks on a blockchain are not the same instrument as shares held in a Fidelity brokerage account. The legal protections, settlement mechanisms, and regulatory frameworks differ significantly. Owning a share of SpaceX in a traditional broker means voting rights, dividend claims where applicable, and decades of securities law standing behind the position. An on-chain representation of those shares may or may not carry the same weight, depending on how the tokenization is structured and where the investor sits. Is that overkill to worry about? No, not when the assets involve pre-IPO shares in OpenAI, SpaceX, and Anthropic. That ambiguity is a feature for crypto-native users and a problem for US-jurisdiction holders. Past SEC enforcement actions against tokenized equity issuers show the agency has not been gentle with these experiments, and any product touching pre-IPO names of this profile will draw regulatory eyes fast.
Worth noting: this is also a competitive signal. Solana, Ethereum L2s, and permissioned RWA chains have all been pitching themselves as the home for tokenized real-world assets. Injective getting to market first with brand-name AI pre-IPOs, not a generic basket, and not another tokenized T-bill, is a meaningful piece of mindshare. Counter to the usual crypto reflex, being first does not automatically mean winning. It does set the reference point. Competitors now have to answer a live OpenAI, SpaceX, and Anthropic product instead of arguing in abstract roadmap language.
What this means
The signal is that the RWA narrative is finally getting a retail-grade product, and it is launching into AI, the strongest story in the broader market right now. For Injective specifically, this gives INJ a fundamentals hook tied to volume, fee capture, and the burn auction. For the wider tokenized stocks category, it is a stress test of whether on-chain pre-IPO markets can scale past the $1 billion perp benchmark Injective set in October 2025. Why does that matter? Because one strong 30-day print turns this from a headline into a category other L1s will rush to copy. If these markets hold depth, expect copycat launches on competing L1s within the quarter.
Watch INJ volume and the on-chain trading depth on OpenAI, SpaceX, and Anthropic over the next 30 days. That is the number that matters. Then watch the regulatory side. Any SEC or CFTC commentary referencing tokenized private equity, especially anything naming OpenAI, SpaceX, or Anthropic directly, will move sentiment fast. Yes, this slightly contradicts the bullish read above; that’s the point. Republic’s involvement gives the launch a more compliant veneer than past attempts, but pre-IPO names of this caliber will not stay under the radar. The clean read on success is simple: sustained volume past day 30, no enforcement headline, and INJ holding above its pre-announcement level.